Jan Willem Kleinovink

Jan Willem Kleinovink

Auto-generated profile, based on publicly available information

Jan Willem Kleinovink

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
LCLuis Cruz
Luis Cruz
RRRodney A. Rosalia
Rodney A. Rosalia
JKJan Willem Kleinovink
Jan Willem Kleinovink
FRFelix Rueda
Felix Rueda
CLClemens W.G.M. Löwik
Clemens W.G.M. Löwik
FOFerry Ossendorp
Ferry Ossendorp

21 February 2017 in OncoImmunology
Verified
Journal Article
Open access
JKJan Willem Kleinovink
Jan Willem Kleinovink
KMKoen A. Marijt
Koen A. Marijt
MSMark J. A. Schoonderwoerd
Mark J. A. Schoonderwoerd
THThorbald van Hall
Thorbald van Hall
FOFerry Ossendorp
Ferry Ossendorp
MFMarieke F. Fransen
Marieke F. Fransen
Immunotherapy with PD-1/PD-L1-blocking antibodies is clinically effective for several tumor types, but the mechanism is not fully understood. PD-L1 expression on tumor biopsies is generally regarded as an inclusion criterion for this cancer therapy. Here, we describe the PD-L1-blocking therapeutic responses of preclinical tumors in which PD-L1 expression was removed from cancer cells, but not from immune infiltrate. Lack of PD-L1 expression on malignant cells delayed tumor outgrowth in a CD8+ T cell-mediated fashion, showing the importance of this molecule in immune suppression. PD-L1 expression was evident on myeloid-infiltrating cells in the microenvironment of these tumors and targeting stromal PD-L1 with blocking antibody therapy had additional antitumor effect, demonstrating that PD-L1 on both malignant cells and immune cells is involved in the mechanism of immunotherapeutic antibodies. Importantly, comparable results were obtained with PD-1-blocking therapy. These findings have implications for inclusion of cancer patients in PD-1/PD-L1 blockade immunotherapies.

1 October 2017 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
JKJan Willem Kleinovink
Jan Willem Kleinovink
MFMarieke F. Fransen
Marieke F. Fransen
CLClemens W. Löwik
Clemens W. Löwik
FOFerry Ossendorp
Ferry Ossendorp
Photodynamic therapy (PDT) is a clinically applied tumor ablation method that reduces tumor burden and may induce T-cell responses, providing a therapeutic option for mutated tumors. In this study, we applied PDT in two mouse tumor models and assessed its effect on outgrowth of PDT-treated and distant untreated tumors. PDT of established tumors resulted in complete tumor eradication in most mice, which were then protected against tumor rechallenge. Correspondingly, the therapeutic effect was abrogated upon systemic depletion of CD8+ T cells, indicating PDT-induced tumor antigen cross-presentation and T-cell activation. In a double-tumor model, PDT of primary tumors induced enhanced infiltration of untreated distant tumors by CD8+ T cells, which significantly delayed their outgrowth. Combination therapy of PDT and CTLA-4–blocking antibodies significantly improved therapeutic efficacy and survival of double-tumor–bearing mice. These results show that local tumor ablation by PDT induces CD8+ T-cell responses crucial for systemic tumor eradication, which can be further enhanced by combination with immune checkpoint blockade. This combination of two clinically applied therapies may be a treatment strategy for advanced cancer without previous knowledge of tumor-specific antigens. Cancer Immunol Res; 5(10); 832–8. ©2017 AACR.

14 March 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JKJan Willem Kleinovink
Jan Willem Kleinovink
PDPieter B. van Driel
Pieter B. van Driel
TSThomas J. Snoeks
Thomas J. Snoeks
NPNatasa Prokopi
Natasa Prokopi
MFMarieke F. Fransen
Marieke F. Fransen
FOFerry Ossendorp
Ferry Ossendorp
Purpose: The efficacy of immunotherapy against advanced cancer may be improved by combination strategies. Photodynamic therapy (PDT) is a local tumor ablation method based on localized activation of a photosensitizer, leading to oxygen radical-induced tumor cell death. PDT can enhance antitumor immune responses by release of antigen and danger signals, supporting combination protocols of PDT with immunotherapy. Experimental Design: We investigated the local and systemic immune effects of PDT after treatment of established tumors. In two independent aggressive mouse tumor models, TC-1 and RMA, we combined PDT with therapeutic vaccination using synthetic long peptides (SLP) containing epitopes from tumor antigens. Results: PDT of established tumors using the photosensitizer Bremachlorin resulted in significant delay of tumor outgrowth. Combination treatment of PDT with therapeutic SLP vaccination cured one third of mice. Importantly, all cured mice were fully protected against subsequent tumor rechallenge, and combination treatment of primary tumors led to eradication of distant secondary tumors, indicating the induction of a systemic antitumor immune response. Indeed, PDT by itself induced a significant CD8+ T-cell response against the tumor, which was increased when combined with SLP vaccination and essential for the therapeutic effect of combination therapy. Conclusions: We show that immunotherapy can be efficiently combined with PDT to eradicate established tumors, based on strong local tumor ablation and the induction of a robust systemic immune response. These results suggest combination of active immunotherapy with tumor ablation by PDT as a feasible novel treatment strategy for advanced cancer. Clin Cancer Res; 22(6); 1459–68. ©2015 AACR.

1 April 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
SRSima Rahimian
Sima Rahimian
MFMarieke F. Fransen
Marieke F. Fransen
JKJan Willem Kleinovink
Jan Willem Kleinovink
JCJonatan Riis Christensen
Jonatan Riis Christensen
MAMaryam Amidi
Maryam Amidi
FOFerry Ossendorp
Ferry Ossendorp

1 August 2015 in Biomaterials
Verified
Journal Article
Closed access
SRSima Rahimian
Sima Rahimian
MFMarieke F. Fransen
Marieke F. Fransen
JKJan Willem Kleinovink
Jan Willem Kleinovink
MAMaryam Amidi
Maryam Amidi
FOFerry Ossendorp
Ferry Ossendorp
WHWim E. Hennink
Wim E. Hennink